Interventions against nutrient-sensing pathways represent an emerging new therapeutic approach for diabetic nephropathy

Clinical and Experimental Nephrology

Volumn 18, Issue 2, 2014, Pages 210-213

  Koya, Daisuke ^a   Kitada, Munehiro ^a   Kume, Shinji ^b   Kanasaki, Keizo ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

AMPK; Autophagy; Diabetic nephropathy; mTORC1; Proteinuria; Sirt1

Indexed keywords

AUTOPHAGY; DIABETIC NEPHROPATHY; HUMAN; NONHUMAN; NUTRIENT; NUTRIENT SENSING PATHWAY; PATHOGENESIS; REVIEW; ANIMAL; DIABETIC NEPHROPATHIES; METABOLISM; PHYSIOLOGY; PODOCYTE;

ADENYLATE KINASE; SIRTUIN;

ADENYLATE KINASE; ANIMALS; AUTOPHAGY; DIABETIC NEPHROPATHIES; PODOCYTES; SIRTUINS;

EID: 84900333241     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0908-3     Document Type: Review

References (56)

1. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17:2974-84. (Pubitemid 44707757)
2. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93:137-88.
3. Kitada M, Zhang Z, Mima A, et al. Molecular mechanisms of diabetic vascular complications. J Diabetes Invest. 2010;1:77-89.
4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-25. (Pubitemid 40770750)
5. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int. 2000;Suppl 77:S3-12.
6. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-66. (Pubitemid 28255657)
7. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 2007;115:69-84. (Pubitemid 46408113)
8. Koya D, Araki S, Haneda M. Therapeutic management of diabetic kidney disease. J Diabetes Invest. 2011;2:248-54.
9. Singh R, Kaushik S, Wang Y, et al. Autophagy regulates lipid metabolism. Nature. 2009;458:1131-5.
10. Yoshizaki T, Kusunoki C, Kondo M, et al. Autophagy regulates inflammation in adipocytes. Biochem Biophys Res Commun. 2012;417:352-7.
11. Huber TB, Edelstein CL, Hartleben B, et al. Emerging role of autophagy in kidney function, diseases and aging. Autophagy. 2012;8:1009-31.
12. Hartleben B, Godel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest. 2010; 120:1084-96.
13. Jiang M, Liu K, Luo J, et al. Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. Am J Pathol. 2010;176:1181-92.
14. Kume S, Uzu T, Horiike K, et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest. 2010;120:1043-55.
15. Liu S, Hartleben B, Kretz O, et al. Autophagy plays a critical role in kidney tubule maintenance, aging and ischemia-reperfusion injury. Autophagy. 2012;8:826-37.
16. Periyasamy-Thandavan S, Jiang M, Wei Q, et al. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int. 2008;74:631-40.
17. Takahashi A, Kimura T, Takabatake Y, et al. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol. 2012;180:517-25.
18. Kume S, Thomas MC, Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes. 2012;61:23-9.
19. Tanaka Y, Kume S, Kitada M, et al.Autophagy as a therapeutic target in diabetic nephropathy. Exp Diabetes Res. 2012;2012:628978.
20. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol. 2007;47:443-67.
21. Chen JK, Chen J, Neilson EG, et al. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol. 2005;16:1384-91. (Pubitemid 41716522)
22. Sakaguchi M, Isono M, Isshiki K, et al. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun. 2006;340:296-301. (Pubitemid 41827680)
23. Yang Y, Wang J, Qin L, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol. 2007;27:495-502. (Pubitemid 47482007)
24. Sataranatarajan K, Mariappan MM, Lee MJ, et al. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol. 2007;171:1733-42.
25. Mori H, Inoki K, Masutani K, et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun. 2009;384:471-5.
26. Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011;121:2197-209.
27. Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121:2181-96.
28. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17:596-603. (Pubitemid 41540408)
29. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280-93.
30. Ravikumar B, Sarkar S, Davies JE. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010;90:1383-435.
31. Ding DF, You N, Wu XM, et al. Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. Am J Nephrol. 2010;31:363-74.
32. Fang L, Zhou Y, Cao H, et al. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemis-induced podocyte injury. PLoS One. 2013;8:e60546.
33. Cammisotto PG, Londono I, Gingras D, et al. Control of glycogen synthase through ADIPOR1-AMPK pathway in renal distal tubules of normal and diabetic rats. Am J Physiol Renal Physiol. 2008;294:F881-9.
34. Sokolovska J, Isajevs S, Sugoka O, et al. Influence of metformin on GLUT1 gene and protein expression in rat streptozotocin diabetes mellitus model. Arch Physiol Biochem. 2010;116: 137-45.
35. Yamazaki T, Tanimoto M, Gohda T, et al. Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KKAy/ Ta mice. Nephron Exp Nephrol. 2009;113:e66-76.
36. Chang CC, Chang CY, Wu YT, et al. Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J Biomed Sci. 2011;18:47.
37. Lee MJ, Feliers D, Mariappan MM, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292:F617-27. (Pubitemid 46220529)
38. Kume S, Uzu T, Araki S, et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol. 2007;18:2715-23. (Pubitemid 47531198)
39. Tanaka Y, Kume S, Araki S, et al. Fenofibrate, a PPARalpha agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int. 2011;79:871-82.
40. Jiang T, Wang Z, Proctor G, et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein- 1c-dependent pathway. J Biol Chem. 2005;280:32317-25. (Pubitemid 41361841)
41. Wang Z, Jiang T, Li J, et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes. 2005;54:2328-35. (Pubitemid 41134259)
42. Saha AK, Ruderman NB. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem. 2003;253:65-70. (Pubitemid 37321713)
43. Canto C, Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci. 2010;67:3407-23.
44. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89:1025-78.
45. Lee JW, Park S, Takahashi Y, et al. The association of AMPK with ULK1 regulates autophagy. PLoS One. 2010;5:e15394.
46. Behrends C, Sowa ME, Gygi SP, et al. Network organization of the human autophagy system. Nature. 2010;466:68-76.
47. Kitada M, Kume S, Takeda-Watanabe A, et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond). 2013;124:153-64.
48. Kitada M, Kume S, Kanasaki K, et al. Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets. 2013;14:622-36.
49. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol. 2009;5:367-73.
50. Imai S, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci. 2010;31:212-20.
51. Lee IH, Cao L, Mostoslavsky R, et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA. 2008;105:3374-9. (Pubitemid 351723560)
52. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD? metabolism and SIRT1 activity. Nature. 2009;458:1056-60.
53. Ghosh HS, McBurney M, Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One. 2010;5:e9199.
54. Tikoo K, Tripathi DN, Kabra DG, et al. Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53. FEBS Lett. 2007;581:1071-8. (Pubitemid 46282743)
55. Tikoo K, Singh K, Kabra D, et al. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res. 2008;42:397-404.
56. Kitada M, Takeda A, Nagai T, et al. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res. 2011;2011:908185.